Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office?
Amidst rising public distrust and a series of high-profile investigations into lawmakers' financial dealings, calls to ban or heavily restrict stock
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 3.8% in the morning session after the U.S. Food and Drug Administration (FDA) granted full approval for its Spikevax COVID-19 vaccine to be used in children. The approval covers children from six months through 11 years of age who are at an elevated risk for severe COVID-19.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older